The use of mesenchymal stromal cells (MSCs) in treating inflammatory bowel disease (IBD) remains under intensive investigation. A study published in The Lancet eBioMedicine evaluates how different methods of delivering MSCs influence their distribution, survival, and therapeutic behavior in a colitis mouse model.
Researchers labeled MSCs with superparamagnetic iron oxide nanoparticles (SPIONs) and tracked them using magnetic particle imaging (MPI), a sensitive, non-radioactive technique. The study compared three administration routes: intravenous (IV), intraperitoneal (IP), and intrarectal (IR).
Findings suggest that intraperitoneal injection allowed for more sustained MSC presence in inflamed colon tissue, with higher survival rates and stronger anti-inflammatory effects. By contrast, IV and IR delivery resulted in shorter retention periods and more dispersed cell distribution. The authors hypothesize that the immune environment of the peritoneal cavity may promote MSC survival and targeted migration.
Further analysis showed that exposure to inflammatory peritoneal fluid enhanced MSC homing behavior, and that pretreatment with interferon-gamma (IFN-γ) improved cell retention at the inflammation site. These findings were confirmed with combined MPI and CT imaging techniques.
Overall, this study provides new insights into how delivery strategies and host environment interactions can impact the therapeutic utility of MSCs in IBD. The use of MPI offers a promising non-invasive method to track cell behavior over time, which may inform future experimental and clinical designs.
=
